Loading...
•
Dec 31, 2024
Arcus Biosciences Q4 2024 Earnings Report
Arcus Biosciences reported its fourth-quarter and full-year 2024 financial results, highlighting pipeline advancements and a strong cash position.
Key Takeaways
Arcus Biosciences reported a net loss of $94 million for Q4 2024, an increase from $81 million in Q4 2023, despite an increase in total revenues to $36 million. The company ended the year with a strong cash position of $992 million, positioning it well for upcoming pivotal readouts.
New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date.
Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan in combination with cabozantinib versus cabozantinib in IO-experienced patients with clear cell renal cell carcinoma (ccRCC) is expected in the first half of 2025.
Arcus completed a $150 million financing and continues to be well positioned to advance its pipeline with $992 million in cash, cash equivalents and marketable securities as of December 31, 2024.
The company expects its cash and investments, together with proceeds from the February 2025 equity financing, to provide funding through initial pivotal read-outs for domvanalimab, quemliclustat and casdatifan.
Revenue by Segment
Forward Guidance
Arcus Biosciences anticipates advancing its pipeline with a strong cash position, initiating new clinical trials, and expecting key data readouts in 2025 and 2026.
Positive Outlook
- Initiation of the Phase 3 PEAK-1 study for casdatifan in IO-experienced ccRCC is expected in the first half of 2025.
- Initial data from the ARC-20 cohort evaluating casdatifan plus cabozantinib are expected to be presented in mid-2025.
- Three new expansion cohorts within ARC-20 will be initiated in the first quarter of 2025, including casdatifan plus zimberelimab in all-comer 1L ccRCC.
- Overall survival data from the Phase 2 EDGE-Gastric study for domvanalimab plus zimberelimab and chemotherapy are expected in fall 2025.
- Arcus anticipates advancing AB801 into expansion cohorts in non-small cell lung cancer (NSCLC) in the second half of 2025.
Challenges Ahead
- Preliminary and interim data are not guarantees that future data will be similar.
- Unexpected emergence of adverse events or other undesirable side effects in investigational products could occur.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...